MedTrace Logo

Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma

NCT02446574 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2017-10-24

No results posted yet for this study

Summary

This is a unicentered phase I/II study to explore the dose of paclitaxel and cisplatin with radiation therapy, and to document the adverse events for further clinical trial.

Conditions

  • Esophageal Neoplasms

Interventions

DRUG

Paclitaxel

starting dose 20mg/m2 qw

DRUG

Cisplatin

dose 25mg/m2 qw

RADIATION

Radiation

60Gy/2Gy/30f

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Zefen Xiao, Professor · Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Science

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02446574 on ClinicalTrials.gov